The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss ...

Osteoarthritis, the most common form of arthritis, is primarily caused by wear and tear on the protective layer of cartilage ...

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weig ...

As OA progresses, it can lead to reduced mobility and bone spurs, further limiting movement. Arthritis includes over 100 ...

A new study suggests that weekly self-injections of the weight loss drug semaglutide could reduce knee pain from moderate osteoarthritis by nearly 50%.

Total hip replacement is routinely recommended for severe hip osteoarthritis, but data from randomized trials are lacking ...

A randomized trial, funded by Novo Nordisk (NVO), found that semaglutide is beneficial for pain reductions in obese people with knee ...

People who lost a significant amount of weight with semaglutide saw major improvements in osteoarthritis knee pain, research ...

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...

Wegovy reduced arthritic knee pain in study subjects with high BMI. Unknown: the exact mechanism or whether it would prevent knee replacement surgery.